Cardiac biomarkers as indicators of right ventricular dysfunction and recovery in chronic thromboembolic pulmonary hypertension patients after balloon pulmonary angioplasty therapy – a cardiac magnetic resonance imaging cohort study

Steffen D. Kriechbaum1,2, Julia M. Vietheer1,2, Christoph B. Wiedenroth3, Felix Rudolph1,2, Marta Barde1,2, Jan-Sebastian Wolter1,2, Moritz Haas1,2, Ulrich Fischer-Rasokat1,2, Maren Weferling1,2, Andreas Rolfl1,2,4, Christian W. Hamm1,2,4, Eckhard Mayer3, Stefan Guth3, Till Keller1,2,4, Fritz C. Roller5,* and Christoph Liebetrau1,2,6,*

1Department of Cardiology, Heart and Thorax Center, Campus Kerckhoff, University of Giessen, Bad Nauheim, Germany; 2German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Frankfurt am Main, Germany; 3Department of Thoracic Surgery, Heart and Thorax Center, Campus Kerckhoff, University of Giessen, Bad Nauheim, Germany; 4Division of Cardiology, Medical Clinic I, Justus Liebig University Giessen, Giessen, Germany; 5Department of Radiology, Justus Liebig University Giessen, Giessen, Germany; 6Cardioangiologisches Centrum Bethanien, Frankfurt am Main, Germany

Abstract

Background: In chronic thromboembolic pulmonary hypertension, right heart failure determines outcome. Balloon pulmonary angioplasty therapy allows right heart recovery, which can be monitored by cardiac magnetic resonance imaging. This study evaluates whether cardiac biomarkers (NT-proBNP, MR-proANP, sST2, and PAPP-A) are associated with cardiac magnetic resonance imaging findings prior to and after balloon pulmonary angioplasty therapy.

Methods: This observational cohort study enrolled 22 chronic thromboembolic pulmonary hypertension patients who underwent balloon pulmonary angioplasty therapy and completed a six-month follow-up including cardiac magnetic resonance imaging. Biomarker levels were compared with findings for right heart morphology and function derived from cardiac magnetic resonance imaging. Biomarker levels were compared with findings for right heart morphology and function derived from cardiac magnetic resonance imaging.

Results: Pulmonary hemodynamics improved after balloon pulmonary angioplasty therapy [pulmonary vascular resistance: 7.7 (6.0–9.0) vs. 4.7 (3.5–5.5) wood units, p < 0.001; mean pulmonary artery pressure 41 (38–47) vs. 32 (28–37) mmHg, p < 0.001]. Cardiac magnetic resonance imaging findings indicated right heart maladaptation at baseline and recovery after therapy [right ventricular end-diastolic volume 192 (141–229) ml vs. 143 (128–172) ml, p = 0.002; right ventricular end-systolic volume 131 (73–157) ml vs. 77 (61–99) ml (p < 0.001); right ventricular ejection fraction (RVEF) 34 (28–41) % vs. 52 (41–54) %; p < 0.001]. Biomarker level cut-offs [NT-proBNP 347 ng/L (area under the curve (AUC) 0.91), MR-proANP 230 pg/L (AUC 0.78), PAPP-A 14.5 mU/L (AUC 0.81), and sST2 48.0 ng/ml (AUC 0.88)] indicated a RVEF/C20 at baseline. The dynamics of NT-proBNP (rs = 0.79; p < 0.001), MR-proANP (rs = 0.80; p < 0.001), and sST2 (rs = 0.49; p = 0.02) correlated inversely with the improvement in RVEF after therapy. A relative decrease of NT-proBNP < 53% (AUC 0.86) and MR-proANP < 24% (AUC 0.82) indicated a limited RVEF response.

Conclusions: In chronic thromboembolic pulmonary hypertension patients, cardiac magnetic resonance imaging findings illustrate right heart failure and recovery after balloon pulmonary angioplasty therapy. Cardiac biomarker levels correlate with right heart parameters at baseline and their dynamics after therapy.

Keywords
Pulmonary hypertension, balloon pulmonary angioplasty, right ventricle function and dysfunction, risk stratification and biomarkers

Date received: 18 May 2021; accepted: 10 October 2021

Pulmonary Circulation 2021; 11(4) 1–10
DOI: 10.1177/20458940211056500

*These authors contributed equally as last authors.
Corresponding author:
Steffen D Kriechbaum, Department of Cardiology, Heart and Thorax Center, Campus Kerckhoff, University of Giessen, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
Email: s.kriechbaum@kerckhoff-klinik.de

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Chronic thromboembolic pulmonary hypertension (CTEPH) is diagnosed in about 3% of patients who survive an acute pulmonary embolism. Progressive impairment of pulmonary hemodynamics burdens the right heart and causes maladaptive morphological and functional right heart remodeling. The ensuing right heart failure is the major determinant of outcome in CTEPH.

Surgical pulmonary endarterectomy is the first-line therapy for CTEPH. In inoperable patients, a sequence of medical therapy with riociguat and balloon pulmonary angioplasty (BPA) is the recommended therapeutic concept. Both therapeutic approaches improve pulmonary hemodynamics and thus allow right heart recovery. Notably, it has been suggested that changes in right heart function under specific therapy for pulmonary hypertension (PH) outperform pulmonary hemodynamics as a predictor of outcome. A structured diagnostic work-up focused on the individual severity of right heart disease is therefore crucial for optimal patient management.

Cardiac magnetic resonance imaging (CMR) is the reference imaging modality for the right heart, facing particularly its complex anatomy with 3D-based measurement of dimensions and function. In PH, CMR provides detailed information about the severity of morphological and functional right heart maladaptation. However, availability, costs, and the necessity of specific expertise limit the use of CMR as a standard approach.

Several noninvasive biomarkers were found to be associated with different aspects of right heart maladaptation and failure. Hemodynamic right heart stress can be estimated by measurement of circulating N-terminal pro-B-type natriuretic peptide (NT-proBNP) and mid-regional pro-atrial natriuretic peptide (MR-proANP). The conversion from hemodynamic stress to cardiac tissue remodeling as a secondary maladaptive response to chronic pressure overload is more difficult to address. Biomarkers as soluble suppression of tumorigenicity 2 (sST2) and pregnancy-associated plasma protein-A (PAPP-A) which are expressed in response to mechanic myocardial stress but also contribute to inflammatory and fibrotic tissue remodeling pathways might be of use in this context. The current study investigates the potential of these biomarkers as indicators of right ventricular function and dimensions by using CMR as a reference method in a cohort of patients with inoperable CTEPH treated by BPA.

Methods

Study population

The present observational cohort study consecutively included 22 patients with confirmed inoperable CTEPH who were treated by BPA, completed a six-month follow-up (6-MFU) after therapy, and underwent CMR at both baseline and follow-up at the study center. The patients were deemed to be inoperable because of peripheral obstructive lesions of the pulmonary arteries. All patients were discussed in a multidisciplinary CTEPH conference to confirm the diagnosis and decide about the individual treatment. The diagnostic and therapeutic management of CTEPH patients at our center was recently published. CMR, which is not routinely performed in all CTEPH patients, was used as supplementary imaging in these 22 patients for extended right heart assessment. The individual decision to perform a CMR was made by the multidisciplinary CTEPH conference.

Only a subset of 15 (68%) patients was treated with riociguat prior to BPA therapy, as prior to 2014 there was no approved medication for CTEPH. Meanwhile, riociguat is recommended in the guidelines. Thus, we adjusted our treatment approach over time, and riociguat is administered at least for three months prior to BPA in inoperable CTEPH patients. There were no changes of medication between the baseline diagnostic assessment prior to interventional BPA therapy and the follow-up.

All patients gave written informed consent. The ethics board of our University approved the study (AZ 43/14). The study protocol conforms to the ethical guidelines of the Declaration of Helsinki.

Right heart catheterization

Right heart catheterization was performed routinely via the right internal jugular vein using a 6F sheath and a standard Swan-Ganz catheter. The medication was not modified prior to or during the procedure.

Balloon pulmonary angioplasty

BPA interventional therapy was performed as a standardized technique as previously published in detail.

Cardiac magnetic resonance imaging

Imaging was performed with a 1.5-T scanner system (Avanto; Siemens Healthineers, Erlangen, Germany; gradient strength and slew rate: SQ-Engine [45 mT/m at 200 T/m/s]) using a six-element phased array cardiac coil and a dedicated CMR protocol containing axial, coronal, and sagittal thoracic survey images, steady-state-free precession sequences (SSFP), CINE in two-chamber view, three-chamber view, four-chamber view, and stacked transaxial and short-axis views from base to apex.

SSFP imaging parameters were slice thickness 8 mm; field of view: 300 × 400 mm; matrix 256 × 154; TR 59.62; and TE 1.15. The SSFP images were obtained during breath-hold, and the LV and RV systolic and diastolic volumes (absolute values) were calculated from short-axis and transaxial CINE images. Measurements were performed on end-diastolic images (first phase after the R-wave trigger) and end-systolic images (CINE with the visually smallest cavity area). Endocardial contours of the left and right ventricle were obtained by manual tracing with exclusion of papillary
muscles and trabeculae from the cavity. Ventricular volumes were estimated using the Simpson rule. The left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) was calculated as [end-diastolic volume – end-systolic volume]/end-diastolic volume. The post-processing was performed with the ARGUS software package (Siemens Syngo MMWP Version VE40A; Siemens Healthineers).

The radiologists who performed the imaging diagnostics were blinded to results from biomarker analysis.

### Laboratory assessment

Venous blood samples for biomarker analysis were collected as serum samples in serum tubes (S-Monovette®, Sarstedt, Nümbrecht, Germany) at baseline prior to BPA therapy and at the 6-MFU, each at the same time as CMR and were processed for storage immediately. All serum samples were transferred to plain uncoated tubes for storage at a temperature of –80°C. The median storage time was 43 (41–46) months. All measurements were carried out batch-wise on once thawed samples by experienced staff blinded to patient characteristics.

NT-proBNP levels were measured using an electrochemiluminescence immunoassay (NT-proBNP assay, Elecsys Analyzer 2010, Roche Diagnostics, Mannheim, Germany). The limit of detection (LOD) for this assay is 5 ng/L; concentrations above the measuring range are reported as >35,000 ng/L. The lowest concentration measurable with a coefficient variation (CV) of 20% is 50.0 ng/L. At the cut-off value of 150 ng/L the CV is <3%.

MR-proANP levels were measured by TRACE (time-resolved amplified cryptate emission) technology (BRAHMS MR-proANP KRYPTOR assay, Kryptor Compact Plus, BRAHMS GmbH, Hennigsdorf, Germany). The LOD is 2.1 pmol/L; concentrations above the measuring range are reported as >10,000 pmol/L. The intra-assay CV is ≤5%; inter-assay CV ≤6.5%.

sST2 levels were measured using an electrochemiluminescence immunoassay (Presage ST2 assay, Critical Diagnostics, San Diego, CA, USA). The LOD is 1.8 ng/ml; concentrations above the measuring range are reported as >200 ng/ml. At a concentration between 33 and 159 ng/ml, the CV ranges from 5.5 to 4.8%.

PAPP-A was measured by time-resolved amplified cryptate emission (BRAHMS PAPP-A KRYPTOR Assay, Thermo Scientific, BRAHMS GmbH, Hennigsdorf, Germany). The LOD is 0.004 U/L; concentrations above the measuring range are reported as >90 U/L. The mean CV is 3.1%.

### Statistical analysis

In consideration of the small study cohort, all continuous variables are expressed as median and interquartile range (IQR). Categorical variables are reported as number and percentage. Subcohorts at baseline, prior to BPA therapy, or at the follow-up were compared using the Mann-Whitney U test for all other continuous variables. The χ² test and Fisher-Yates test were used for categorical variables. Parameters that were obtained at baseline and at the 6-MFU were subjected to paired sample testing using the Wilcoxon signed-rank test. Correlations were analyzed using bivariate Spearman correlation (rₛ).

The study assessed the diagnostic performance of non-invasive biomarkers to indicate severe right heart dysfunction at baseline and the change of right heart function after BPA therapy, using receiver operating characteristics (ROC). In the literature, inconsistent data about optimal RVEF cut-off values to predict outcome in cardiac diseases are reported, however, a RVEF ≤35% derived from CMR was strongly associated to worse outcome in patients with pulmonary artery hypertension. Accordingly, we predefined severe right heart dysfunction as a RVEF ≤35%, quantified by CMR.

We further defined a limited change of right heart function after therapy as a relative change of RVEF ≤25% compared to the baseline RVEF. Biomarkers with a correlation (rₛ ≥ 0.5) to RVEF change after therapy were analyzed in this context.

Results are presented as area under the curve (AUC) with corresponding 95% confidence intervals (CIs). The optimal cut-off values with regard to study outcomes were calculated using Youden index quantification.

To assess the prognostic performance of optimal biomarker cut-off levels with regard to study outcomes, sensitivity, specificity, and negative (NPV) and positive (PPV) predictive values were calculated. Results are presented as odds ratios (OR) with corresponding 95% CIs.

Statistics were performed with SPSS software (IBM Corp., Armonk, NY, USA), version 21.0. A two-tailed p value <0.05 was considered to be statistically significant.

### Results

#### Characteristics of the study cohort and treatment effects

The sociodemographic data and comorbidities of all 22 patients (12 women; median age [IQR] 70 [63–77] y) enrolled in the study are presented in Table 1. In all patients, the BPA therapy was indicated due to obstructive lesions of the pulmonary arteries, which were too peripheral for a surgical pulmonary endarterectomy. The intervention- al treatment included 122 BPA sessions, a median of 6 (5–7) per patient, with a median number of 10 (9–12) treated vessels. Table 1 shows the effects of therapy on physical capacity and hemodynamic findings.

#### Biomarker measurement and CMR findings at baseline

The detailed findings from CMR and biomarker measurements at baseline are given in Table 1. The majority (n = 19;
86%) of patients showed normal left ventricular dimensions and function at baseline. In three patients, the LVEF was mildly (n = 1) or moderately (n = 2) impaired. The levels of all four biomarkers measured, particularly the natriuretic peptides, correlated with right ventricular dimensions and RVEF at baseline (Table 2).

A total of 14 (64%) patients showed severely impaired RVEF of ≤35% at baseline. These patients were characterized by higher baseline levels of NT-proBNP [RVEF ≤ 35%: 1427 (931–3377) ng/L vs. RVEF > 35%: 214 (45–779) ng/L; p = 0.001], sST2 [RVEF ≤ 35%: 65.3 (51.7–96.8) ng/mL vs. RVEF > 35%: 42.9 (39.0–50.7) ng/mL; p = 0.003], PAPP-A [RVEF ≤ 35%: 20.6 (14.9–29.5) mU/L vs. RVEF > 35%: 13.0 (8.7–17.3) mU/L; p = 0.02], and MR-proANP [RVEF ≤ 35%: 261 (105–422) pmol/L vs. RVEF > 35%: 122 (58–149) pmol/L; p = 0.04].

An NT-proBNP level of 347 ng/L (AUC 0.91), an MR-proANP level of 230 pg/L (AUC 0.78), a PAPP-A level of 14.5 mU/L (AUC 0.82) respectively was indicative for an unchanged RVEF (Table 3).

None of the patients (n = 4) with all biomarker levels below the listed cut-off values at baseline showed an RVEF ≤ 35% at baseline.

**Changes in biomarker and CMR findings during therapy**

After BPA, morphological and functional right heart parameters improved (Table 1). The absolute levels of all four biomarkers decreased after therapy (Table 1). The relative change in the RVEF correlated with the relative change in the levels of NT-proBNP (Fig. 1a), MR-proANP (Fig. 1b), and sST2 (Fig. 1c) after therapy, but not with changes in PAPP-A (Table 2). A total of 13 (59%) patients had an RVEF of ≥50% after BPA. A group of eight (36%) patients showed no significant (<25%) change of their RVEF after therapy. A relative change of the NT-proBNP level less than 53% (AUC 0.86) and a change of the MR-proANP level less than 24% (AUC 0.82) respectively was indicative for an unchanged RVEF (Table 3).

**Discussion**

The key findings of the current study were (I) CMR findings indicate a morphological and functional right heart impairment in CTEPH patients at baseline that improves after BPA therapy; (II) NT-proBNP, MR-proANP, sST2, and PAPP-A levels correlate with right ventricular dimensions and function at baseline; and (III) the relative change of biomarker levels, particularly NT-proBNP and MR-proANP, after therapy correlates with the relative improvement in right ventricular dimensions and function after BPA therapy.

**CMR and biomarker findings at baseline**

In CTEPH, impaired pulmonary hemodynamics burden the right heart, which leads to compensatory right heart remodeling and finally chronic right heart failure. Considering this sequence, there is no doubt that the extent of pulmonary hemodynamic impairment is a determinant of disease severity in PH. However, the extent of maladaptive right heart remodeling as a fatal consequence can vary and was suggested to be an even more consistent determinant of disease severity and outcome in PH than altered hemodynamics.

CMR provides morphological and functional parameters of right heart maladaptation in pulmonary hypertension. In comparison to reference values, gathered from CMR in healthy individuals, the CTEPH patients in our cohort were characterized by distinct right ventricular dilatation and reduced RVEF, which is comparable to other CTEPH cohorts.

Although CMR is the primary method for right heart assessment, it is unsuitable for a regular follow-up. Non-invasive biomarkers address different aspects of cardiac remodeling and might thus be a feasible tool for the assessment of structural and functional right heart impairment in PH. Circulating levels of natriuretic peptides mirror myocardial stress due to pressure and volume overload and are established diagnostic and prognostic markers in heart failure. In PH, natriuretic peptides are associated with secondary right heart failure and assessment of these biomarkers is recommended for screening, individual risk stratification, and therapy monitoring. The current study found a strong correlation of NT-proBNP with right ventricular dimensions and function prior to BPA therapy, which is in line with the findings from other series.

The current guidelines on PH suggest an NT-proBNP level >300 ng/L as a cut-off to distinguish low-risk and elevated-risk patients. Consistent with this, patients in our cohort with a severely impaired RVEF were identified by an NT-proBNP level ≥347 ng/L and showed a median level of 1427 ng/L at baseline, whereas patients with an RVEF > 35% had a median level of 214 ng/L. The correlation of MR-proANP levels with right heart CMR parameters was inferior to that of NT-proBNP, which might be explained by its mechanism of expression. MR-proANP is produced in response to atrial stretch due to hemodynamic stress, and MR-proANP levels are related to right atrial pressure in CTEPH. Considering that right atrial stress follows right ventricular deterioration in PH, right atrial failure is a strong indicator of right ventricular failure, but not vice versa.

In its role as a receptor for interleukin (IL)-33, ST2 regulates the tissue-protective effects of this cytokine and exists in both transmembrane (promoting) and soluble (opposing) isoforms. An upregulation of the IL-33-(s)ST2 pathway was detected in relation to inflammation, tissue injury, and remodeling and in the context of cardiac stress.
### Table 1. Patient characteristics and diagnostic findings (N = 22).

| Sociodemographic characteristics and comorbidities | Baseline | Follow-up |
|---------------------------------------------------|----------|-----------|
| Age, years, median (IQR)                          | 70 (63–77) | 70 (63–77) |
| Female sex, n (%)                                 | 12 (55)   | 21 (95)   |
| Body mass index, kg/m², median (IQR)              | 24.3 (22.4–27.0) | 24.3 (22.4–27.0) |
| Diabetes mellitus, n (%)                          | None      | None      |
| Arterial hypertension, n (%)                      | 13 (59)   | 14 (64)   |
| Smoking, n (%)                                     | 8 (36)    | 1 (5)     |
| Coronary artery disease, n (%)                    | 4 (18)    | 1 (5)     |
| Atrial fibrillation, n (%)                        | 2 (9)     | 1 (5)     |
| Glomerular filtration rate, mL/min, median (IQR)  | 81 (68–93)| 81 (68–93)|
| Creatinine, μmol/L, median (IQR)                  | 0.92 (0.75–0.99) | 0.92 (0.75–0.99) |
| History of cancer, n (%)                          | 5 (23)    | 1 (5)     |
| Chronic obstructive pulmonary disease, n (%)      | 1 (5)     | 1 (5)     |
| History acute pulmonary embolism, n (%)          | 18 (82)   | 15 (68)   |
| History of splenectomy, n (%)                     | 1 (5)     | 1 (5)     |
| History of chronic inflammatory disease, n (%)    | None      | None      |

| Medication                                         | Baseline | Follow-up |
|---------------------------------------------------|----------|-----------|
| Novel oral anticoagulants (%)                     | 16 (73)  | 21 (95)   |
| Vitamin K antagonist (%)                           | 6 (27)   | 1 (5)     |
| Guanylate cyclase stimulator (%); Riociguat 1–7.5 mg/d | 14 (64)  | 15 (68)   |
| Endothelin receptor antagonist; Bosentan 250 mg, Macitentan 10 mg | 3 (14)   | 3 (14)    |
| Inhibitor of Phosphodiesterase 5; Tadalafil 40 mg  | 1 (5)    | 1 (5)     |

| Clinical status                                    | Baseline | Follow-up |
|---------------------------------------------------|----------|-----------|
| WHO FC I/II/III/IV                                 | 0/0/13/9 | 14/6/2/0  |
| 6-MWD, m (IQR)                                    | 387 (333–472) | 427 (357–451) |
| Echocardiography                                   | 55 (55–58) | 55 (55–58) |
| TAPSE, mm (IQR)                                   | 20 (17–22) | 24 (22–26) |
| Right heart catheterization meanPAP, mmHg (IQR)    | 41 (38–47) | 32 (28–37) |
| Relative change in meanPAP, %                      | Decrease of 22 (12–29) | Decrease of 22 (12–29) |
| PVR, wood units (IQR)                              | 7.7 (6.0–9.0) | 4.7 (3.5–5.5) |
| Cardiac index, L/min/m² (IQR)                      | 2.4 (2.1–2.8) | 2.7 (2.4–3.1) |
| Cardiac index, %                                   | 6 (5–9)   | 5 (4–8)   |
| Cardiac magnetic resonance imaging                 | 9 (8–11)  | 9 (8–11)  |
| LVEDV, ml (IQR)                                    | 87 (81–99) | 108 (95–130) |
| LVEF, % (IQR)                                      | 33 (22–45) | 37 (26–54) |
| LVESV, ml (IQR)                                    | 65 (56–72) | 65 (62–70) |
| RVEDV, ml (IQR)                                    | 192 (141–229) | 143 (128–172) |
| RVESV index, ml/m² (IQR)                           | 100 (74–129) | 84 (71–97) |
| RVESV ml (IQR)                                     | 131 (72–157) | 77 (61–99) |
| RVESV index, ml/m² (IQR)                           | 76 (44–87) | 46 (34–52) |
| RVSV ml (IQR)                                      | 66 (51–74) | 73 (67–86) |
| RVSV index, ml/m² (IQR)                            | 37 (28–43) | 39 (35–51) |
| RVEF, % (IQR)                                      | 34 (28–41) | 52 (41–54) |

| Biomarkers                                         | Baseline | Follow-up |
|---------------------------------------------------|----------|-----------|
| NT-proBNP, ng/L                                   | 1122 (295–2365) | 149 (71–341) |
| sST2, ng/mL                                        | 52.6 (43.7–76.1) | 44.7 (37.6–58.4) |
| PAPP-A, mU/L                                       | 17.2 (13.1–28.6) | 11.7 (10.3–13.5) |
| MR-proANP, pmol/L                                  | 145 (102–285) | 125 (58–155) |

Values are presented as n (%) or median (IQR). Abbreviations: LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; meanPAP: mean pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance; RAP: right atrial pressure; RVEDV: right ventricular end-diastolic volume; RVEF: right ventricular ejection fraction; RVESV: right ventricular end-systolic volume; TAPSE: tricuspid annular plane systolic excursion; WHO FC = World Health Organization functional class; 6-MWD: 6-minute walk distance; 6-MFU: 6-month follow-up.
Recent studies reported elevated sST2 levels in PH.33 Thus, serum levels associated with a severe impairment of RVEF in our study. Protein pathways, 40 which promote inflammation, associated with sST2 levels correlated with right heart parameters from CMR: they were significantly elevated in patients with an RVEF < 35%, and a level > 48.0 ng/mL was associated with a severe impairment of RVEF in our study. Pregnancy-associated plasma protein-A (PAPP-A) is a regulator of insulin-like growth factor (IGF)/IGF-binding protein pathways,40 which promote inflammation, and remodeling.13,34–36 Moreover, there is evidence for an association of elevated sST2 levels with right ventricular dilatation and dysfunction and increased mortality in PH.33 Recent studies reported elevated sST2 levels in PH and CTEPH patients compared with healthy controls.23,38 Thus, serum levels > 65 ng/mL were associated with severe hemodynamic impairment and mortality.23,39 Consistent with these findings, sST2 levels correlated with right heart parameters from CMR: they were significantly elevated in patients with an RVEF < 35%, and a level > 48.0 ng/mL was associated with a severe impairment of RVEF in our study.

### Table 2. Bivariate Spearman correlation of biomarker levels and right heart parameters derived from CMR findings and other diagnostic findings.

| Parameter | NT-proBNP (ng/L) | MR-proANP (pmol/L) | sST2 (ng/ml) | PAPP-A (mU/L) |
|-----------|-----------------|-------------------|-------------|---------------|
| Baseline  |                 |                   |             |               |
| RVEDV, ml | $r_s = 0.68; p = 0.001$ | $r_s = 0.34; p = 0.12$ | $r_s = 0.36; p = 0.11$ | $r_s = 0.46; p = 0.03$ |
| RVEDV index, ml/m² | $r_s = 0.73; p = 0.001$ | $r_s = 0.49; p = 0.02$ | $r_s = 0.45; p = 0.04$ | $r_s = 0.47; p = 0.03$ |
| RVEF, % | $r_s = 0.80; p < 0.001$ | $r_s = 0.46; p < 0.001$ | $r_s = 0.47; p = 0.03$ | $r_s = 0.48; p = 0.02$ |
| RVEF, mmHg | $r_s = 0.81; p < 0.001$ | $r_s = 0.56; p < 0.001$ | $r_s = 0.58; p = 0.004$ | $r_s = 0.42; p = 0.05$ |
| PVR, wood units | $r_s = 0.27; p = 0.04$ | $r_s = 0.07; p < 0.001$ | $r_s = 0.39; p = 0.03$ | $r_s = 0.22; p = 0.04$ |
| Cardiac index, L/min/m² | $r_s = 0.73; p < 0.001$ | $r_s = 0.67; p < 0.001$ | $r_s = 0.61; p = 0.003$ | $r_s = 0.13; p = 0.57$ |
| RAP, mmHg | $r_s = 0.57; p = 0.03$ | $r_s = 0.44; p = 0.04$ | $r_s = 0.48; p = 0.03$ | $r_s = 0.1; p = 0.66$ |

### Table 3. Prognostic performance of biomarkers.

| Biomarker level at baseline for the identification of patients (N = 14/22) with severely impaired right ventricular ejection fraction | Cut-off value | AUC (95% CI) | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | NPV (95% CI) | PPV (95% CI) | OR (95% CI) |
|-------------------------------------------------|---------------|---------------|--------------------------|--------------------------|--------------|--------------|--------------|
| NT-proBNP, ng/L 347 | 0.91 (0.79–1) | 92 (64–100) | 75 (35–97) | 85 (44–97) | 87 (66–96) | 36 (2.7–481) |
| sST2, ng/mL 48.0 | 0.00 (0.72–1) | 93 (66–100) | 75 (35–97) | 86 (46–98) | 87 (66–96) | 39 (2.9–519) |
| PAPP-A, mU/L 14.5 | 0.81 (0.60–1) | 86 (57–98) | 75 (35–97) | 75 (44–92) | 86 (64–95) | 18 (2–161) |
| MR-proANP, pmol/L 230 | 0.78 (0.58–0.99) | 57 (29–82) | 100 (63–100) | 57 (42–71) | 100 (100) | not calculateda |

### Table 3. Prognostic performance of biomarkers.

| Relative change from baseline to 6-month follow-up | Cut-off value (%) | AUC (95% CI) | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | NPV (95% CI) | PPV (95% CI) | OR (95% CI) |
|-------------------------------------------------|-------------------|---------------|--------------------------|--------------------------|--------------|--------------|--------------|
| NT-proBNP change, % $<$33 | 0.86 (0.66–1) | 88 (47–100) | 92 (66–100) | 93 (68–99) | 87 (51–98) | 91 (4.9–1687) |
| MR-proANP change, % $<$24 | 0.82 (0.63–1) | 88 (47–100) | 79 (49–95) | 92 (64–99) | 07 (45–87) | 26 (2.3–298) |

Abbreviations: LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; meanPAP: mean pulmonary artery pressure; MR-proANP: mid-regional pro-atrial natriuretic peptide; NT-proBNP: N-terminal pro-B-type natriuretic peptide; PAPP-A: pregnancy-associated plasma protein-A; PVR: pulmonary vascular resistance; RAP: right atrial pressure; RVEDV: right ventricular end-diastolic volume; RVEF: right ventricular ejection fraction; RVEDV index: right ventricular end-systolic volume; sST2: soluble suppression of tumorigenicity 2.

Abbreviations: AUC: area under the curve; CI: confidence interval; MR-proANP: mid-regional pro-atrial natriuretic peptide; NT-proBNP: N-terminal pro-B-type natriuretic peptide; OR: odds ratio; PAPP-A: pregnancy-associated plasma protein-A; sST2: soluble suppression of tumorigenicity 2; NPV: negative predictive value; PPV: positive predictive value.

*aNo patient with a severely impaired RVEF showed a MR-proANP level below the cut-off.
anti-apoptosis, and proliferation in various cell types such as endothelial and smooth muscle cells. There is some evidence for an involvement of PAPP-A and IGF-I/IGF-receptor signaling in PH. Recently, our group found elevated PAPP-A levels in patients with CTEPH and non-CTEPH PH compared with healthy controls that were not associated with pulmonary hemodynamics. In the present study, PAPP-A levels moderately correlated with right heart parameters from CMR: patients with an RVEF < 35% had elevated PAPP-A levels, and a level > 14.5 mU/L was associated with an RVEF ≤ 35%.

**Dynamics of CMR and biomarker findings after BPA therapy**

BPA therapy improves pulmonary hemodynamics and thus allows right heart recovery with consequent positive effects on clinical symptoms and physical capacity. Right heart reverse remodeling, manifested by a normalization of right heart dimensions and improved RVEF, was illustrated by imaging studies. In pulmonary artery hypertension, the RVEF and the indexed right ventricular end-systolic volume (RVESVi), gathered from CMR at baseline, distinguished patients with a low, intermediate, or high risk of one-year mortality. Remarkably, the outcome of patients who moved to the low-risk RVEF or RVESVi group after specific PH therapy, documented by a follow-up CMR, was comparable to those patients with low-risk characteristics at baseline.

This again confirms right heart recovery as the major therapy goal in CTEPH. In line with other series, right ventricular dimensions and RVEF improved after BPA therapy in the vast majority of patients in our study, which was documented by CMR findings. As a consequence of right heart dilatation, interventricular septum shift, and septum dyssynchrony, concomitant left heart impairment, with a reduced left ventricular filling, is regularly observed in PH. Concomitant to right heart recovery, CMR findings documented a reexpansion of the left ventricle after BPA therapy in our cohort, which might allow improved left ventricular filling.

Although an optimal assessment of right heart conditions should be a major focus of CTEPH follow-up regimes, routine assessment by CMR would not seem to be applicable due to the limitations mentioned. A few studies reported a correlation of NT-proBNP and sST2 with right heart dimensions and function and their response to therapy in PH. In our cohort, there was a significant decrease in the levels of all four biomarkers measured after BPA therapy. Particularly the changes in NT-proBNP (RVESVi: $r_s = 0.83; p < 0.001$; RVEF: $r_s = -0.79; p < 0.001$) and MR-proANP (RVESVi: $r_s = 0.89; p < 0.001$; RVEF: $r_s = -0.80; p < 0.001$) strongly correlated with the dynamics of right heart dimensions and function after therapy.

A limited decrease of the baseline NT-proBNP level (<53%) or MR-proANP level (<24%) was indicative for an unchanged RVEF after therapy. Including NT-pro-BNP and MR-proANP measurement in the follow-up examinations of CTEPH patients might be an easily applied tool for noninvasive right heart “imaging.”

Certain limitations of the study need to be mentioned. This study included a relatively small number of patients. Furthermore, CMR is not included in the routine diagnostic work-up of CTEPH patients. The decision to perform a CMR was made by the interdisciplinary CTEPH conference. Thus, the study consecutively included patients with a CMR, but not those CTEPH patients in between without a CMR. The results, particularly those concerning the diagnostic strength of biomarkers to predict CMR findings, should be interpreted as hypothesis-generating findings.

In conclusion, CMR findings illustrate significant right heart remodeling and failure in CTEPH patients. The therapy allows right heart recovery, particularly an improvement of right ventricular function. In consideration of the mentioned limitations, our study suggests that cardiac biomarkers can identify patients with a severely reduced RVEF at baseline, CMR documents changes in RV reverse remodeling, and changes in biomarker levels correlate with RV functional improvement after therapy.
Acknowledgements
We thank Elizabeth Martinson, PhD, from the KHF\textsuperscript{i} Editorial Office for her editorial assistance. We thank Dimitri Grün from the Franz-Groedel Institute for his assistance in statistical analysis.

Conflict of interest
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CBW has received speaker fees and/or consultative honoraria from Actelion, AOP Orphan Pharmaceuticals AG, Bayer AG, BTG, MSD, and Pfizer; MH received a lecture honoraria from Daiichi-Sankyo and Pfizer; AR received a lecture honoraria from Astra Zeneca, Boehringer Ingelheim and Pfizer-Bristol-Myers Squibb; CWH received a lecture or consulting honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, GSK, Daiichi-Sankyo and Pfizer-Bristol-Myers Squibb; EM received lecture or consulting honoraria from Actelion, Bayer, MSD, GSK, Pfizer and MSD; SG received a speaker or consulting honoraria from Actelion, Bayer, GSK and Pfizer; TK received speaker fees from Abbott; CL received a lecture or consulting honoraria from Abbott, Astra Zeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Daiichi-Sankyo and Pfizer-Bristol-Myers Squibb. SJK, JMV, FR, MB, JSW, UFR, MW and FCR report no relationships that could be construed as a conflict of interest.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and publication of this article: This research project is based on a cohort that is part of the Kerckhoff Biomarker Registry (Bioreg), which is financially supported by the Kerckhoff Heart Research Institute (KHF\textsuperscript{i}) and the German Center for Cardiovascular Research (DZHK). We are also grateful to the William G. Kerckhoff-Foundation, Bad Nauheim, Germany for research funding. The current evaluation is supported by the grant of the Kerckhoff Foundation and is associated with the Collaborative Research Center 1213 (SFB 1213, Central Project 01). The sponsors had no influence on the study design, statistical analyses, or drafting of the manuscript.

Ethical approval
The ethics board of the Justus Liebig University of Giessen approved the study (AZ 43/14).

Guarantor
SDK and CBL.

Authors’ contribution
SDK: study conception, interpretation of data, data management, first draft of the manuscript; JMV: interpretation of data, proofreading of the manuscript; CBW: treatment of patients, interpretation of data, proofreading of the manuscript; FR and MB: follow-up of patients, data management, proofreading of the manuscript; JSW: statistics, interpretation of data, proofreading of the manuscript; MH: treatment of patients, interpretation of data, proofreading of the manuscript; UFR, MW, AR, CWH, EM, SG, and TK: interpretation of data, proofreading of the manuscript; FCR: CMR diagnostics, interpretation of data, proofreading of the manuscript; CL: study conception, treatment of patients, interpretation of data, proofreading of the manuscript.

ORCID iDs
Steffen D. Kriechbaum \(\text{\textcopyright} \) https://orcid.org/0000-0002-0448-6445
Felix Rudolph \(\text{\textcopyright} \) https://orcid.org/0000-0003-4948-6438
Till Keller \(\text{\textcopyright} \) https://orcid.org/0000-0002-0895-6491

References
1. Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. \textit{Eur Respir J} 2019; 53: 1801915.
2. Simonneau G, Torbicki A, Dorfmüller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. \textit{Eur Respir Rev} 2017; 26: 160112.
3. Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH): results from an international prospective registry. \textit{Circulation} 2016; 133: 859–871.
4. Wilkins H, Konstantinides S, Lang IM, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): updated recommendations from the Cologne Consensus Conference 2018. \textit{Int J Cardiol} 2018; 272s: 69–78.
5. Olsson KM, Wiedenroth CB, Kamp JC, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. \textit{Eur Respir J} 2017; 49: 1602409.
6. Guth S, Wiedenroth CB, Kramm T, et al. Pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension. \textit{Expert Rev Respir Med} 2016; 10: 673–684.
7. Van De Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. \textit{J Am Coll Cardiol} 2011; 58: 2511–2519.
8. Spruijt OA, Di Pasqua MC, Bogaard HJ, et al. Serial assessment of right ventricular systolic function in patients with precapillary pulmonary hypertension using simple echocardiographic parameters: a comparison with cardiac magnetic resonance imaging. \textit{J Cardiothorac Vasc Anesth} 2017; 31: 182–188.
9. van de Veerdonk MC, Bogaard HJ and Voelkel NF. The right ventricle and pulmonary hypertension. \textit{Hear Fail Rev} 2016; 21: 259–271.
10. Waziri F, Ringgaard S, Mellemkjær S, et al. Long-term changes of right ventricular myocardial deformation and remodeling studied by cardiac magnetic resonance imaging in patients with chronic thromboembolic pulmonary hypertension following pulmonary thromboendarterectomy. \textit{Int J Cardiol} 2020; 300: 282–288.
11. Kriechbaum SD, Wiedenroth CB, Wolter J-SS, et al. N-terminal pro-B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. \textit{J Heart Lung Transplant} 2018; 37: 639–646.
12. Kriechbaum SD, Scherwitz L, Wiedenroth CB, et al. Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH. \textit{ERJ Open Res} 2020; 6: 00356–00202.
13. Pascual-Figal DA and Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. \textit{Am J Cardiol} 2015; 115: 3b–7b.

8 | Right heart function in CTEPH - biomarkers and CMR  Kriechbaum et al.
14. Funayama A, Shishido T, Nitsu S, et al. Serum pregnancy-associated plasma protein A in patients with heart failure. J Card Fail 2011; 17: 819–826.

15. Wiedenroth CB, Ghofrani HA, Adameit MSD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm Circ 2018; 8: 2045894018783996.

16. Huang KC, Lin JL and Lin LC. Transthoracic echocardiography: improved practice by real-time 3D acquisition and automation. In: Dumitrescu S, Tintoiu I and Underwood M (eds) Right heart pathology: from mechanism to management. Heidelberg: Springer, 2018, pp. 573–586.

17. Berman M, Gopalan D, Sharples L, et al. Right ventricular reverse remodeling after pulmonary endarterectomy: magnetic resonance imaging and clinical and right heart catheterization assessment. Pulm Circ 2014; 4: 36–44.

18. Schoenfeld C, Hinrichs JB, Olsson KM, et al. Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients. Eur Radiol 2019; 29: 1693–1702.

19. Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014; 43: 1394–1402.

20. Kawel-Boehm N, Maceira A, Valsangiacomoe-Buechel ER, et al. Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson 2015; 17: 29.

21. Foppa M, Arora G, Gona P, et al. Right ventricular volumes and systolic function by cardiac magnetic resonance and the impact of sex, age, and obesity in a longitudinally followed cohort free of pulmonary and cardiovascular disease: the Framingham heart study. Circ Cardiovasc Imaging 2016; 9: e003810.

22. Reesink HJ, Marcus JT, Tulevski II, et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg 2007; 4: 36–44.

23. Kriechbaum SD, Wiedenroth CB, Peters K, et al. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension. Biomarkers 2020; 25: 578–586.

24. Kriechbaum SD, Rudolph F, Wiedenroth CB, et al. Pregnancy-associated plasma protein A – a new indicator of pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension? Respir Res 2020; 21: 204.

25. Reesink HJ, Tulevski II, Marcus JT, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007; 84: 537–543.

26. Carlonagno G, Messali G, Melillo RM, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol 2013; 168: 1545–1547.

27. de Boer RA, Daniels LB, Maisel AS, et al. State of the art: newer biomarkers in heart failure. Eur J Heart Fail 2015; 17: 559–569.

28. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2015; 37: 2129–2200.

29. Galié N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorse. Eur Heart J 2016; 37: 67–119.

30. Mello MM, Watte G, Altmaeier S, et al. Relationship between right atrium area and right ventricular ejection fraction on magnetic resonance imaging: comparison with other prognostic markers in patients with pulmonary arterial hypertension. Radiol Bras 2019; 52: 351–355.

31. Nakagawa Y, Nishikimi T and Kuwahara K. Atrial and brain natriuretic peptides: hormones secreted from the heart. Peptides 2019; 111: 18–25.

32. Mueller T and Dieplinger B. The Presage(R) ST2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 2013; 13: 13–30.

33. Luk KS, Ip C, Gong MQ, et al. A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension. J Geriatr Cardiol 2017; 14: 766–771.

34. Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010; 55: 243–250.

35. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538–1549.

36. Sanchez-Mas J, Lax A, Asensio-Lopez Mdel C, et al. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Eur J Clin Invest 2014; 44: 643–651.

37. Chida A, Sato H, Shintani M, et al. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful bio-marker for predicting outcome of childhood pulmonary arterial hypertension. Cire J 2014; 78: 436–442.

38. Mirna M, Rohm I, Jrak P, et al. Analysis of novel cardiovascular biomarkers in patients with pulmonary hypertension (PH). Hear Lung Circ 2020; 29: 337–344.

39. Plácido R, Cortez-Dias N, Robalo Martins S, et al. Prognostic stratification in pulmonary hypertension: a multimarker approach. Rev Port Cardiol (English Ed) 2017; 36: 111–125.

40. Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 1999; 96: 3149–3153.

41. Troncoso R, Ibarra C, Vicencio JM, et al. New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab 2014; 25: 128–137.

42. Pfaffle R, Kiess W and Klamm J. Downstream insulin-like growth factor. Endocr Dev 2012; 23: 42–51.

43. Yang Q, Sun M, Ramchandran R, et al. IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: role of epigenetic regulation. Vascul Pharmacol 2015; 73: 20–31.

44. Sun M, Ramchandran R, Chen J, et al. Smooth muscle insulin-like growth factor-1 mediates hypoxia-induced pulmonary hypertension in neonatal mice. Am J Respir Cell Mol Biol 2016; 55: 779–791.
45. Broch K, Murbraech K, Ragnarsson A, et al. Echocardiographic evidence of right ventricular functional improvement after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. *J Hear Lung Transpl* 2016; 35: 80–86.

46. Sumimoto K, Tanaka H, Mukai J, et al. Effects of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension on remodeling in right-sided heart. *Int J Cardiovasc Imaging* 2020; 36: 1053–1060.

47. Lewis RA, Johns CS, Cogliano M, et al. Identification of cardiac magnetic resonance imaging thresholds for risk stratification in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2020; 201: 458–468.

48. Sanz J, Sánchez-Quintana D, Bossone E, et al. Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review. *J Am Coll Cardiol* 2019; 73: 1463–1482.

49. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J* 2006; 28: 1190–1194.

50. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. *Eur Respir J* 2007; 29: 737–744.